Greenstein AJ, Lachman P, Sachat DB. Perforating and non-perforating indication for repeated operations in Crohn's disease : evidence for two clinical forms. Gut 1988 ; 13 : 5885-92.
Spence DT, Mayberry JF. Clinical indices in inflammatory bowel disease. In : Allan RN, Rhodes JM, Hanauer SB, Keighley MR, Alexander-Williams J, Fazio VW, eds Inflammatory bowel diseases. New York : Churchill Livingstone, 1997 : 335-41.
De Dombal FT, Softley A. IOIBD report no 1 : Observer variation in calculating indices of severity and activity in Crohn's disease. Special report. Gut 1987 ; 28 : 474-81
Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, et al. Correlation between clinical activity, endoscopic severity and biological parameters in colonic or ileocolonic Crohn's disease A prospective multicentre study of 121 cases. Gut 1994 ; 35 : 231-5.
Hodgson HJF. Laboratory markers of inflammatory bowel disease. In : Allan RN, Rhodes JM, Hanauer SB, Keighley MR, Alexander-Williams J, Fazio VW, eds. Inflammatory bowel disease. New York : Churchill Livingstone, 1997 . 329-34.
Tromm A, Tromm CD, Hüppe D, Schwegler U, Krieg M, May B. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease Scand J Gastroenterol 1992 , 27 : 774-8.
Matsuura T, West GA, Klein JS, Ferraris L, Fiocchi C. Soluble interleukin 2 and CD8 and CD4 receptors in inflammatory bowel disease. Gastroenterology 1992 ; 102 : 2006-14.
Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993 ; 104 : 1285-92.
Modigliani R, Mary JY and the Getaid. Reproductibility of colonoscopic findings in Crohn's disease. Dig Dis Sci 1987 , 32 . 439-42.
Landi B, N'Guyen A, Cortot A, Soulé JC, René E, Gendre JP, et al. Endoscopic monitoring of Crohn's disease treatment : a prospective, randomized clinical trial. Gastroenterology 1992 ; 102 : 1647-53.
Bretagne JF, Moisan A, Darnault P. Épreuves isotopiques au cours des maladies inflammatoires de l'intestin. In . Modigliani R, ed. Maladies inflammatoires de l'intestin. Paris : Doin éditeurs 1988 , 91-103.
Brignola C, Campieri M, Bazzocchi G, Farruggia P, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986 ; 91 : 1490-4.
Brignola C, Iannone P, Belloki C, De Simone G, Bassein L, Giochetti P, et al. Prediction of relapse in patients with Crohn's disease in remission : a simplified index using laboratory tests, enhanced by clinical characteristics. Eur J Gastroenterol Hepatol 1994 ; 6 : 955-61.
Sahmoun T, Hoctin-Boes G, Modigliani R, Bitoun A, Colombel JF, Soulé JC, et al. Identifying patients with a high risk of relapse in quiescent Crohn's disease. Gut 1995 ; 37 : 811-8.
Brignola C, Campieri M, Farruggia P, Tragnone A, Pasquali S, Iannone P, et al. The possible utility of steroids in prevention of relapses of Crohn's disease in remission. A preliminary study. J Clin Gastroenterol 1998 ; 10 : 631-4.
Louis E, Belaiche J, Van Kemseke C, Schaaf N, Mahieu P, Mary JY. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci 1995 ; 40 : 1750-6.
Louis E, Belaiche J, Van Kemseke C, Franchimont D, De Groot D, Gueenen V, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease Eur J Gastroenterol Hepatol 1997 ; 9 : 939-44.
Wyatt J, Vogelsgang H, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993 ; 314 : 1437-9.
Franchimont D, Louis E, Simon S, Belaiche J. Intestinal permeability in Crohn's disease. Acta Gastroenterol Belge 1996 ; 59 : 15-9.
De Vos M. Cost benefict of longterm follow-up of uncomplicated Crohn's disease. Acta Gastroenterol Belge 1998 ; 61 : 11-2.
Volgelsang H, Ferenci P, Woloszeznk W, Resch H, Herold C, Frotz S, et al. Bone disease in vitamin D deficient patients with Crohn's disease. Dig Dis Sci 1989 ; 34 : 1094-9.
Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy P, Montbrun T, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992 ; 37 : 1396-403.
Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M, et al. Bone loss in patients with inflammatory bowel disease : a prospective study. Osteoporosis International 1995 ; 5 : 156-60.
Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995 ; 108 : 417-22.
Sachar DB. Cancer in Crohn's disease : dispelling the myths. Gut 1994 ; 35 : 1507-8.
Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large bowel cancer in Crohn's disease with colonic involvement. Lancet 1990 ; 336 357-9
Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn's disease : a comparison of colorectal cancer risk in extensive colitis. Gut 1994 ; 35 : 1590-2.
Choi PM. Malignancy in Crohn's disease. In . Prantera C, Korelitz BL, eds. Crohn's disease. New York : Marcel Dekker, 1996 : 509-27.
Marteau P, Nelet F, Le Lu C, Devaux C. Adverse events in patients treated with 5-aminosalicylic acid : 1993-1994 pharmaco-vigilance report for Pentasa in France Aliment Pharmacol Ther 1996 ; 10 : 949-56.
Lémann M. Immunosuppressive therapy and immunomodulation in inflammatory bowel disease : new data. Research and Clinical Forums 1995 ; 17 198-211
Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JF, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994 ; 343 : 1249-52
Lémann M, Bonhomme P, Bittoun A, Messing B, Modigliani R, Rambaud JC. Traitement de la maladie de Crohn par l'azathioprine ou la 6-mercaptopurine. Étude rétrospective chez 126 malades. Gastroenterol Clin Biol 1990 ; 14 : 548-54
Present DH, Meltzer SJ, Krumholtz MP, Wolke A Lorelitz BI. 6-mercaptopurine in the management of inflammatory bowel disease : short and long-term toxicity. Ann Inter Med 1989 ; 111 : 641-9.
Larvol L, Soulé JC. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. N Engl J Med 1994 ; 331 : 883-4
Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJG, Clark ML. Safety of azathioprine in inflammatory bowel disease. Gastroenterology 1990 , 99 . 444-6.
Francella A, Dayan A, Rubin P, Chapman M. Present D. 6-mercaptopurine (6-MP) is safe therapy for child bearing patients with inflammatory bowel disease (IBD) . a case controlled study. Gastroenterology 1996 ; 110 . A 909 (abstract).
Rajapakse RO, Korelitz BI, Zlatanic J, Baiocco PJ, Gleim GM. Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease. Gastroenterology 1998 ; 114 : G4336 (abstract)
Allan RN. Inflammatory bowel disease, the oral contraceptive pill and pregnancy. In : Allan RN, Rhodes JM, Hanauer SB, Keighley MR, Alexander-Williams J, Fazio VW, eds. Inflammatory bowel disease. New York : Churchill Livingstone, 1997 : 671-3.
Connell WR, Sheffield MA, Kamm JK, Ritchie JK, Hawley PR, Lennard-Jones JE Lower gastrointestinal malignancy in Crohn's disease. Gut 1994 ; 35 : 347-52.
Belaiche J, Louis E. Les récidives postopératoires de la maladie de Crohn. In . Lémann M, Modigliani R, eds. Maladies inflammatoires de l'intestin, 2e édition. Paris : Doin éditeur, 1998 : 119-32.
